Heart-racing? NASCAR picks cardiovascular partner

Ladies and gentlemen, start your rrr, rrr, rrr-rivaroxaban? NASCAR, the auto racing aficionado organization, announced that Janssen Pharmaceuticals has become its official cardiovascular partner.

Janssen, maker of the anticoagulant rivaroxaban (Xarelto), is partnering with NASCAR on promotions that include prominent race car driver Brian Vickers. Vickers shares his experience with treatment after episodes of deep vein thrombosis, which temporarily sidelined his racing career. Rivaroxaban has been approved by the FDA to treat deep vein thrombosis or pulmonary embolism and to reduce the risk of recurrent deep vein thrombosis and pulmonary embolism following initial treatment.

Jannsen co-sponsored a custom “TreatMyClot.com” Toyota Camry in a recent race that coincided with National Blood Clot Awareness Month. Vickers placed seventh, according to his website, which advances him in overall points and may secure a placement in upcoming races.

Candace Stuart, Contributor

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."